Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor

NCT07203846 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

ACS - Acute Coronary Syndrome
Ticagrelor
Microbiota
Platelet Aggregation
Myocardial Infarction (MI)
Blood Platelets
Drug Effects
Platelet Aggregation Inhibitors
Drug Resistance
Platelet Function Tests
Dysbiosis
Anti-Bacterial Agents
Rifaximin

Interventions

DRUG: Rifaximin

Sponsor

Collegium Medicum w Bydgoszczy

Collaborators

[object Object]